17 results about "A-transferase activity" patented technology

The present invention relates to a method for producing α-sialyl-β-D-galactoside saccharides, particularly α-sialyl-(2→3)-β-D-galactoside saccharides and α-sialyl-(2→6)-β-D-galactoside saccharides, from a β-D-galactoside saccharide, a sialic acid donor, and an enzyme with β-galactoside α-sialyltransferase activity. The enzymes with β-galactoside α-sialyltransferase activity used herein do not exhibit catalytic activity towards the hydrolysis of cytidine 5'-monophospho-N-acetyl-neuraminic acid to cytidine and N-acetyl-neuraminic acid. The method can be performed in vitro and in vivo using a genetically engineered cell comprising a nucleic acid encoding said enzyme. Further, said process may be adapted to produce the sialic acid donor CMP-Neu5Ac from low-cost substrates N-acetyl-D-glucosamine (GlcNAc), pyruvate, a cytidine phosphate (CMP, CDP or CTP) and polyphosphate in a single reaction mixture with a set of optionally immobilized or optionally co-immobilized enzymes comprising N-acylglucoamine 2-epimerase (AGE), an N-acetylneuraminate lyase (NAL), an N-acylneuraminate cytidylyltransferase (CSS), optional a uridine kinase (UDK), a uridine monophosphate kinase and a polyphosphate kinase 3 (PPK3).

A method for producing modified cells lacking mannosyl(alpha-1,3)-glycoprotein beta-1,2-N-acetylglucosamine transferase 1 ("MGAT1") activity is provided. The MGAT1 activity-deficient CHO cell line produced by this method is also provided. A method for producing glycoproteins is further disclosed.

The application discloses a kind of compositions for inhibiting uridine diphosphate glucuronosyltransferase 1A9 activity and application thereof, belong to medical technology field.The composition includes two kinds or more in alpha-antiarol, beta-antiarol, gamma-antiarol, garcinia C, garcinia D, 8-deoxy-garcinol, garcinol and 3-isoantiarol.The application verifies by experiment that the extract of fruit mountain bamboo has higher affinity and stronger inhibitory activity to UGT1A9 in alpha-antiarol, beta-antiarol, gamma-antiarol, garcinia C, garcinia D, 8-deoxy-garcinol, garcinol and 3-isoantiarol, and the components have higher biological activity and safety, can be used as the selective inhibitor of UGT1A9, to inhibit the metabolism of clinical immunosuppressive drug mycophenolic acid, increase mycophenolic acid exposure, prolong the half-life of mycophenolic acid, improve mycophenolic acid efficacy.

A method for producing a modified cell deficient in mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase 1 (“MGAT1”) activity. Also provided is a CHO cell line deficient in MGAT1 activity produced by the method. Further disclosed are methods for producing a glycoprotein.

The invention discloses a recombinant Pasteurella multocida-sourced uridine diphosphate glucuronide transferase (PmHS2) mutant and a preparation method thereof, and relates to the technical field of biology, the mutant is obtained by cloning a coding gene to a pET26b (+) vector, transforming BL21 (DE3) Escherichia coli competent cells, and then transforming the recombinant Pasteurella multocida-sourced uridine diphosphate glucuronide transferase (PmHS2) to a pET26b (+) vector. And carrying out IPTG (isopropyl-beta-d-thiogalactoside) induced culture, ultrasonication and nickel affinity chromatography purification to obtain high-purity protein. Compared with wild type recombinant PmHS2, the activity of N-acetyl glucosamino transferase of the mutant is improved by 70%, the residual activity is 67.1% after the mutant is stored at room temperature for 5 days, the soluble expression quantity is improved by 6 times, and the mutant and the preparation method have the advantages of high catalytic efficiency, high stability and high solubility, and the mutant and the preparation method are mature in process, controllable in cost and suitable for industrial production. The method can be efficiently used in the fields of heparin and derivative synthesis, traditional Chinese medicine active ingredient glycosylation and the like, is suitable for large-scale production and has a wide application prospect.

The invention discloses application of protoflavin and derivatives thereof in preparation of an METTL7B inhibitor, and belongs to the technical field of medical preparations. The invention aims to solve the technical problem of how to inhibit the enzyme activity of METTL7B. To this end, the present application provides a method for inhibiting the enzymatic activity of methyltransferase METTL7B, the method comprising the step of contacting a substance with methyltransferase METTL7B to inhibit the enzymatic activity of methyltransferase METTL7B, the substance is protoflavin, a stereoisomer thereof, a solvate thereof, a pharmaceutically acceptable salt thereof, a hydrate or solvate of the pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable modifier thereof. The invention discloses application of protoflavin or derivatives thereof in inhibition of activity of methyltransferase METTL7B and application of protoflavin or derivatives thereof in preparation of drugs for treating cancers for the first time, and provides a new research target and a potential new treatment mode for cancers.

Methods and systems are provided for generating and utilizing a genetically engineered bacterium comprising a modification in a gene regulating nitrogen fixation or assimilation, wherein the modification in the gene regulating nitrogen fixation or assimilation results in one or more of: constitutive expression of a nifA gene in nitrogen limiting and non-nitrogen limiting conditions, activity of nifA in non-nitrogen limiting conditions, decreased uridylyl-transferase activity of GlnD, decreased adenylyl-removing activity of GlnE, and increased ammonium excretion.

The application discloses a multifunctional pea polypeptide and a preparation method thereof, and belongs to the technical field of functional polypeptides. The method comprises the following steps: extracting pea protein isolate by using an ultrasonic-assisted alkali dissolution and acid precipitation method; preparing the pea polypeptide by using a steam explosion technology-assisted enzymatic hydrolysis method; and evaluating the functional activity of the pea polypeptide by using a chemical method. The pea polypeptide prepared by the method has the functions of antioxidation, blood pressure reduction and blood sugar reduction. In the application, the pea polypeptide is obtained by using steam explosion treatment to assist enzymatic hydrolysis, and the above functions of the pea polypeptide are improved, so that the DPPH free radical scavenging capacity is 92%, the ABTS free radical scavenging capacity is 93%, the O2 ‑ free radical scavenging capacity is 98%, the angiotensin transferase ACE activity inhibition rate is 68%, the alpha-glucosidase activity inhibition rate is 75%, the alpha-amylase activity inhibition rate is 71%, and the foundation is laid for the wide application of the pea polypeptide in functional foods or special diet foods.

This application relates to a microorganism in which the activity of pyruvate dehydrogenase complex dihydrolipoyllysine residue acetyltransferase is improved, and to a method for producing L-amino acids using the same.

Methods to identify modulators of histone acetyltransferases are described. Modulators of histone acetyltransferases can be used to treat individuals. In some instances, modulators of histone acetyltransferases are utilized to treat individuals having a neoplasm.

The present invention provides a microorganism that has been modified to express a gene encoding a protein having arginine:glycine amidinotransferase (AGAT) activity and increase the production of glycine from L-serine by enhancing L-serine hydroxymethyltransferase activity, as well as a method for producing guanidinoacetic acid (GAA) by fermentation of such a microorganism, and a method for producing creatine.

This invention discloses a flavonol glycosyltransferase EsGT_F from *Epimedium sagittatum* and its applications. The EsGT_F gene provided by this invention is 1398 bp in length, encoding 466 amino acids. After cloning the *Epimedium sagittatum* flavonol glycosyltransferase gene EsGT_F, a prokaryotic expression system was constructed. The expressed protein exhibits flavonol glycosyltransferase activity, catalyzing the conversion of cymosin I to icariin. The *Epimedium sagittatum* flavonol glycosyltransferase and its encoding gene provided by this invention offer important gene elements and corresponding technical methods for the microbial cell factory production of the active ingredients of *Epimedium*, and have significant application prospects.

The present application relates to: a novel protein having an acetyl-CoA acetyltransferase activity; a polynucleotide encoding the protein; a microorganism comprising the protein, the polynucleotide encoding the protein, or a vector comprising the polynucleotide; and a method for producing polyhydroxyalkanoate (PHA), comprising a step of culturing the microorganism in a medium.

Provided are amino acid sequences for modified, truncated forms of human GlcNA-1-Phosphotransferase (PTase) that retain phosphotransferase activity and the ability to phosphorylate proteins, lysosomal or non-lysosomal. Truncated forms of PTase lacking or with modified linkers and / or lacking the C-terminal transmembrane and cytosolic domain are demonstrated to retain phosphotransferase activity and the ability to phosphorylate target proteins.

The present invention provides microorganisms that have been modified to express a gene encoding a protein having arginine:glycine amidinotransferase (AGAT) activity and to increase the production of glycine from L-serine, as well as methods for producing guanidinoacetic acid (GAA) by fermentation of such microorganisms, and methods for producing creatine.

The present disclosure relates to the production of mixtures of sialylated Human Milk Oligosaccharides (HMOs), in particular 3′SL and 6′SL and genetically modified cells and their use in said production, where the cells express a heterologous sialyltransferase with dual α-2,3-sialyltransferase / α-2,6-sialyltransferase activity.

The invention discloses a method for improving cadmium resistance of gynostemma pentaphyllum and reducing cadmium accumulation through 5-azacytidine and application, and belongs to the technical field of plant cultivation and epigenetic regulation. In order to solve the problems that the growth of the gynostemma pentaphylla is inhibited and the cadmium content of the overground part exceeds the standard due to cadmium pollution, 5-azacytidine and CdCl2 are applied in a water culture stage for composite stress treatment, the 5-azacytidine is used for inhibiting the activity of DNA methyltransferase and reducing the methylation level of genomic DNA, so that the expression of a cadmium transport gene is regulated and controlled, and the cadmium content of the overground part is reduced. Transferring of cadmium to the overground part is inhibited, and enrichment of cadmium in the root system is promoted; meanwhile, an antioxidant enzyme system is activated, oxidative damage is relieved, and saponin synthesis is promoted. The method is mainly used for cultivating gynostemma pentaphyllum in a cadmium-polluted environment, so that the cadmium resistance of the gynostemma pentaphyllum is enhanced, the cadmium content of medicinal parts is reduced, and the safety and quality of medicinal materials are guaranteed.